Evidence map›Paper›PMID 21538672›Full record

ArticlePharmacoepidemiology and drug safety2011

Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004.

Andrea V Margulis, Niteesh K Choudhry, Colin R Dormuth, Sebastian Schneeweiss

Abstract read
In one paragraph

Article in Pharmacoepidemiology and drug safety, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Adherence to guidelines for the prescription of secondary prevention medication at hospital discharge after acute coronary syndrome: a multicentre study.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2015
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Andrea V MargulisDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02120, USA. andreamargulis@post.harvard.edu
Niteesh K Choudhry
Colin R Dormuth
Sebastian Schneeweiss

Funding

Analyzing Complex Healthcare Data to Determine Causality of Observed Drug EffectsR01LM010213 · NLM · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHNEEWEISS, SEBASTIAN G. · 2009 to 2012
$1.6M
Assessment of Treatment Effects in High-Dimensional, Routine Care Claims DataRC4HL106376 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHNEEWEISS, SEBASTIAN G. · 2010 to 2010
$1.3M
NHLBI NIH HHS RC4‐HL102023NHLBI NIH HHS RC4 HL106376NLM NIH HHS R01 LM010213
6 · The paper itself

Abstract

purposeMyocardial infarction (MI) survivors benefit from receiving secondary prevention, including beta-blockers, angiotensin-blocking agents, and statins, as recommended by guidelines. Compliance with these guidelines is suboptimal. We sought to describe the initiation of secondary prevention in MI survivors, and to describe the variation in initiation by discharging the hospital, the physician, and the physician "responsible" for secondary prevention prescribing decisions in British Columbia in 1997-2004.

methodsWe assembled a cohort of 28,613 patients discharged alive from the hospital after their first MI and were not readmitted within 30 days. Physicians responsible for prescribing post-MI secondary prevention medications were identified as the physicians prescribing the greatest number of cardiac medications (post-discharge cardiac prescribers). We used multilevel logistic regression to assess the variation in drug initiation at discharging hospital, discharging physician, and post-discharge cardiac prescriber levels, which were adjusted for patient and provider characteristics during the study period.

resultsBeta-blockers initiation increased from 56 to 71% over the 8-year study period; angiotensin-converting enzyme/angiotensin II receptor blocker initiation increased from 37 to 70%, and statin initiation increased from 22 to 66% (0-28% for high-potency statins). The probability for initiating an average patient with the study drugs varied widely in age-sex-adjusted models at the hospital and physician levels. Further adjustment did not meaningfully change findings. The variation was largest for statins. The maximum between-provider variance was found for high-potency statins in 2003-2004 at the post-discharge cardiac prescriber level.

conclusionsStudy-drug initiation is increasing among MI survivors, but the variation in initiation is wide between discharging hospitals and physicians.

Indexed as

Practice Patterns, Physicians'Adrenergic beta-AntagonistsAdultAgedAged, 80 and overAge FactorsAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersBritish ColumbiaCohort StudiesDrug Therapy, CombinationFemaleHospitalsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID21538672
PMCPMC3522852

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.